Translational Stroke Research Using a Rabbit Embolic Stroke Model: A Correlative Analysis Hypothesis for Novel Therapy Development by Lapchak, Paul A.
REVIEW ARTICLE
Translational Stroke Research Using a Rabbit Embolic
Stroke Model: A Correlative Analysis Hypothesis
for Novel Therapy Development
Paul A. Lapchak
Received: 11 January 2010 /Revised: 28 January 2010 /Accepted: 11 March 2010 /Published online: 2 April 2010
# The Author(s) 2010. This article is published with open access at Springerlink.com
Abstract Alteplase (tissue plasminogen activator, tPA) is
currently the only FDA-approved treatment that can be given
toacuteischemicstroke(AIS)patientsifpatientspresentwithin
3 h of an ischemic stroke. After 14 years of alteplase clinical
research, evidence now suggests that the therapeutic treatment
window can be expanded 4.5 h, but this is not formally
approved by the FDA. Even though there remains a significant
risk of intracerebral hemorrhage associated with alteplase
administration, there is an increased chance of favorable
outcome with tPA treatment. Over the last 30 years, the use
of preclinical models has assisted with the search for new
effective treatments for stroke, but there has been difficulty
with the translation of efficacy from animals to humans.
Current research focuses on the development of new and
potentially useful thrombolytics, neuroprotective agents, and
devices which are also being tested for efficacy in preclinical
and clinical trials. One model in particular, the rabbit small clot
embolic stroke model (RSCEM) which was developed to test
tPA for efficacy, remains the only preclinical model used to
gain FDA approval of a therapeutic for stroke. Correlative
analyses from existing preclinical translational studies and
clinical trials indicate that there is a therapeutic window ratio
(ARR) of 2.43-3 between the RSCEM and AIS patients. In
conclusion, the RSCEM can be used as an effective transla-







AIS is the third leading cause of death and the leading
cause of adult disability in the USA [1] with an estimated
cost of $68.9 billion. According to the current 2009 USA
stroke statistics [2], each year, approximately 795,000
people suffer a stroke (one every 40 s with one mortality
every 3 min), 75% of which are first strokes and the
remainder recurrent attacks. Annually, 18% of stroke victims
die from the brain attack. Gender differentially impacts
mortality rates with 60.6% of females dying from a stroke
compared to 39% of male victims [2]. The World Health
Organization estimates that 15 million people suffer strokes
worldwide. More than five million stroke victims die from
the brain insult and approximately 5.5 million are perma-
nently disabled (www.strokecenter.org/patients/stats.htm).
Ischemic Stroke Classification
According to the National Institutes of Neurological
Disorders and Stroke (NINDS) type classification and the
population-based study documented by Petty et al. [3, 4],
AIS can be classified as the following:
1. Cardioembolic stroke in which the embolism arises
from a cardiac source such as atrial fibrillation with
intra-atrial thrombus, congestive heart failure, myocar-
dial infarction, valve disease, and aneurysm surgery;
2. Atheroembolic stroke which can be associated with
narrowing of a cervicocephalic artery (i.e., large artery
to artery stroke) including the carotid, vertebral, basilar,
middle cerebral, anterior cerebral, or posterior cerebral
artery; and
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motor, sensorimotor, or sensory strokes in addition to
ataxic hemiparesis and result from thrombosis in one of
the deep penetrating branches from larger cerebral
arteries.
According to Petty and colleagues [3, 4], in patients with
strokes with known causes, cardioembolic stroke is a
predominant subtype in AIS patients making up approxi-
mately 29% of the population, whereas both atheroembolic
and lacunar stroke are represented by 16% of the
population. However, it remains that the majority of strokes
(39%) do not have a known cause and are identified as
“cause unknown.” Independent of the type of stroke, the
“clot” is responsible for the interruption of cerebral blood
flow [5–7], thereby changing tissue metabolism, depleting
cells of energy stores, and, depending upon the duration of
the initial insult, can trigger a cascade of excitotoxicity, free
radical formation, blood–brain barrier (BBB) injury, and
inflammation [6]. Reduced blood flow and severe oxygen
deficiency leads to an ischemic brain area comprising a
central core of severely ischemic tissue surrounded by a
tissue zone consisting of moderate ischemic tissue with
preserved cellular metabolism and viability [8–10]. For a
yet undefined period of time after a stroke, there appears to
be a region of salvageable tissue commonly referred to as a
“penumbra” to target with novel therapies in order to
improve cellular functions.
Current Treatment
The only FDA-approved treatment for stroke is the thrombo-
lytic,tissueplasminogenactivator(tPA,Alteplase®,Activase®)
marketed by Genentech Inc. in the USA and Boehringer
Ingelheim in Europe as actilyse®. tPA is a plasminogen
activator that promotes thrombolysis by activating the
endogenous fibrinolytic system [5, 11–13]. In brief, tPA
catalyzes the conversion of plasminogen to plasmin, which
in turn degrades fibrin and leads to clot lysis and cerebral
reperfusion. Alteplase has been shown to be effective up to
4.5 h after a stroke [14, 15]. However, alteplase therapy has
been linked to serious, even fatal, side effects [5]. Although
the mortality rate at 90 days post-treatment is similar in
alteplase and placebo groups, the short-term incidence of
symptomatic intracerebral hemorrhage (sICH) is signifi-
cantly higher in tPA-treated patients. In the NINDS tPA trial
[16], sICH occurred in 6.4% of alteplase-treated patients
within 36 h of stroke onset, a significant increase compared
to patients receiving placebo [16]. For over 14 years, the
developmentandrefinementoftPAhascontinued.Inthemost
recent ECASS III trial [14], the incidence of ICH and sICH
was higher with alteplase than with placebo (27.0% vs.
17.6%, p=0.001, and 2.4% vs. 0.2%, p=0.008), respectively.
However, the mortality rate did not differ significantly
between the alteplase and placebo groups (7.7% and 8.4%,
respectively, p=0.68) and there was no significant difference
in the rate of other serious adverse events. Thus, even though
tPA is effective at causing partial or complete clot lyisis with
an expanded therapeutic window, transient or permanent re-
occlusion was observed in about 35% of cases [16], and
these patients typically exhibited worse clinical outcome than
those with stable alteplase-induced recanalization.
In 1999, the Stroke Therapy Academic Industry Round-
table (STAIR) Committee [17] put forth recommendations
for the effective development of new therapies of AIS. The
report arbitrarily defined some of the animal models and
methodologies that should be used to develop treatments,
including the possible use of rats and primates. However,
STAIR indicated that there are “currently there are no
standardized, well-accepted models of stroke recovery in
primates, although limited experience exists with baboons.”
As far as a primate model, STAIR also cites the use of
squirrel monkeys, macaques, and marmosets. Indeed,
marmosets were used during the development of NXY-
059 (Cerovive) by Astra-Zeneca, which led the most
devastating failure of NXY-059 [18, 19]. Was failure of
NXY-059 predictable based upon the pharmacological
characteristics of NXY-059 and therapeutic window in
preclinical stroke models? Yes, if one considers the
chemical properties and pharmacological profile of NXY-
059 in preclinical studies.
Clearly, with only one effective FDA-approved stroke
treatment and with the recent failure of a promising
pharmacological therapeutic candidate, there remains a
need to develop treatments for stroke. However, the
question is how can the scientific community develop
effective stroke treatment? Is there one or more preclinical
animal models that can be used for effective translational
research? This review will specifically focus on the
scientific justification for the use of a rabbit embolic stroke
model as a possible gold standard assay to develop
thrombolytics, neuroprotective agents, and devices to treat
AIS. Since reviews of other stroke models have already
been documented in the scientific literature, the reader is
referred to those reviews for more information [20–27].
Translational Stroke Research
Investigators in translational research seek to use a
predictable animal model of AIS to develop an effective
stroke therapy. In accordance with the original STAIR
criteria and recommendations [17], a therapeutic agent
being developed for the treatment of AIS should be tested
in an animal model that mimics stroke in humans and uses
functional recovery as an outcome measure because
functional recovery is a major end point in clinical trials
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considered successful if it results in a favorable clinical
outcome, an outcome primarily based upon motor functions
and overall well-being evaluated using one of two standard
clinical outcome measures: the National Institutes of Health
Stroke Scale (NIHSS) and the modified Rankin Scale
(mRS), both of which have been extensively reviewed in
the literature [28–32].
Is there an animal model of embolic stroke that parallels
stroke in patients? The answer is both yes and no! This
year, 2010, is the silver (25th) anniversary of the rabbit
small clot embolic stroke model (RSCEM) that was used to
demonstrate that tPA could improve behavior or clinical
rating scores [33] when administered following a stroke.
There were also other reports using a rabbit embolic stroke
model to study tPA pharmacology from Fisher and
colleagues [34, 35]. They showed that tPA induced partial
or complete thrombus dissolution without the development
of developed macroscopic cerebral hemorrhage. Moreover,
Seibert and colleagues used a rabbit embolic stroke model
to demonstrate that tPA can increase cerebral reperfusion
and reduce infarct volume measured using the mitochon-
drial activity stain 2,3,5-triphenyltetrazolium chloride [36].
A similar result was also demonstrated by Gross et al. [37].
The RSCEM has been further characterized as a model
where embolism using non-autologous clots leads to
reduced cerebral blood flow, cell death, and decreased
cortical energetics [38–40].
The original embolic stroke paper [33] described the
embolization of awake unanesthetized rabbits in order to
determine both the initial effects of embolization and the
long-term effect of embolization on behavior. The absence
of anesthesia is an advantage when conducting stroke
research to parallel human stroke since many known
anesthetics have “neuroprotective” activities that can
confound scientific results [41–43].
The use of clinical rating scores (a behavioral end point)
parallels some components of the mRS scale that is used for
stroke patients, a common neurological end point in most
clinical trials of ischemic stroke. Initially, the investigators
used a three-tiered rating scale for behavioral analysis of
embolized rabbits: normal, abnormal, or dead [33]. The
original RSCEM paper describing the efficacy of tPA did
not reveal the percentage of dead animals included in the
study or whether tPA affected mortality. Nevertheless, to
date, the RSCEM is still used, and the clinical scoring
which predominantly measures motor function includes
death as an outcome to parallel the death event that occurs
in AIS clinical trials [44–47]. The inclusion of death may
be important when designing preclinical stroke animal
studies since death is an outcome measured in human
studies (see NIHSS and mRS) [28–32]. For instance, in the
original NINDS tPA clinical trial publication, even though
mortality between groups was not significantly different,
mortality at 3 months was 17% in the tPA group and 21%
in the placebo group (p=0.30) [16]. In the more recent
ECASS publication, mortality was also not different
between groups and only accounted for 7.7% of patients
in the tPA group and 8.4% in the placebo group [14]. While
there are clear differences between the mortality rates in the
NINDS rtPA trial and the ECASS tPA trial, there were no
differences in each of the individual trials. Indeed, the
inclusion of mortality rate or death in rabbits may point to,
at least in part, why the RSCEM was predictive of tPA
efficacy in humans.
Even if one accepted standard behavioral measures short
of death, the behaviors that predict drug and/or device
efficacy in humans are largely unknown, and outcome
measures in animal models are evaluated at short times
following ischemia (1–21 days) and not at the times required
for approval by the FDA in humans (3 months or more). The
bottom line is that death as an end point is extremely useful
and must be included as an outcome measure in animal
models of stroke. This is in contrast to current practice for
the majority of researchers conducting stroke research in
models other than the RSCEM where early deaths are
simply excluded from the experiment. This ultimately leads
to skewed results and erroneous findings when final results
are calculated based only upon surviving animals.
There has also been significant study of tPA using rodent
models of embolic stroke. Table 1 documents some of the
beneficial and detrimental effects of tPA by leading rodent
stroke researchers. As is clearly evident from the literature,
tPA is effective at reducing infarct volume in rodents
following large clot embolic strokes and providing some
behavioral improvement [48–53]. From the cited literature,
it appears that tPA is beneficially effective in rodent
between 2 and 4 h following a stroke and ineffective or
detrimental thereafter [51]. The detrimental effects even
include significantly increased infarct volume compared to
the vehicle control group [53]. Moreover, in the rodent
embolic stroke model, tPA produces significant hemorrhag-
ic transformation, which is dependent upon both the dose
and time of tPA administration [49–51]. The knowledge of
the dosing and therapeutic window effects of tPA in rodent
models comes from a survey of studies from multiple
investigators since there are no comprehensive dose–
response and therapeutic window studies in rodent embolic
stroke models that can be directly compared to the RSCEM
studies described above. Nevertheless, tPA does save brain
in rodents and improves behavior, but the dosing and
timing relationships are unclear.
To summarize, tPA has a therapeutic window of 1–1 . 5hi n
theRSCEMandaneffectivetherapeuticwindowof3–4.5hin
AIS patients. Thus, for this thrombolytic agent, the therapeu-
tic window AIS/RSCEM ratio (ARR) is approximately 3.
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Alteplase
The NINDS Study [16] initially established that intravenous
rtPA improved neurological outcome in approximately 160
patients out of 1,000 treated, preferably when given within
3 h of stroke onset. However, after 6 h, alteplase was
ineffective and neurological outcome was not different from
that in the placebo group. Based upon this study, the FDA
approved the use of alteplase in the USA for selected
patients with AIS [16]. Follow-up studies further empha-
sized the need for rapid treatment with alteplase after AIS
onset [5, 14, 54–61]. Recently, alteplase has been shown to
be an effective stroke treatment up to 4.5 h after a stroke
[14]. It is interesting to note that in patients who underwent
intravenous alteplase therapy within 90 min of stroke onset,
functional outcome at 3 months was excellent and was
sustained for at least 12 months. Subsequent analysis
confirmed that there is a time effect such that earlier treatment
leads to greater likelihood of a beneficial effect [62]. In
addition, in patients responding to tPA, the treatment proved
to be cost-effective as there was reduced long-term hospital-
ization and improved rehabilitation [5, 54–61].
One of the unexpected successes of the initial NINDS
tPA trial in human stroke was that tPA was effective not
only for presumed cardioembolic stroke but also for
presumed atheroembolic and small vessel lacunar stroke
[16]. Indeed, the NINDS rtPA trial publication [16]
indicated that 62% of subjects improved with tPA com-
pared to 41.5% with placebo following lacunar stroke, and
38% of subjects improved with tPA compared to 29% with
placebo following cardioembolic stroke [16]. These data
did not provoke changes in thinking about the pathogenesis
of different types of stroke and may have been de-
emphasized because of uncertainties about criteria for
lacunar stroke. The efficacy of tPA in lacunar stroke likely
had a role in accounting for the fact that infarct volume was
not predictive of outcome in the NINDS tPA stroke trial
[16]. Of note is that the increases of endogenous blood
levels of tPA and PAI are similar in cardioembolic,
thromboembolic, and lacunar stroke [63]. Finally, a recent
study using standard TOAST criteria for the three major
types of stroke examined 90 consecutive patients and
demonstrated that the efficacy of tPA in cardioembolic,
thromboembolic large vessel, and in lacunar stroke was
comparable [64].
The importance of the role of tPA in large vessel
thromboembolic stroke and small vessel lacunar stroke
has not been addressed by either basic or clinical stroke
scientists. On the clinical side, these data suggest that clot
formation plays a key patho-etiological role in lacunar
stroke and that in situ thrombosis associated with athe-
roembolic stroke may also be very important in stroke
pathogenesis [65]. The efficacy of tPA in cardioembolic,
large vessel atheroembolic and small vessel lacunar stroke
has important implications for the predictive value of animal
models of stroke. Though everyone agrees that embolism
with an autologous clot likely mimics cardioembolic stroke
fairly well, there is no accepted model with a well-defined
clinically relevant behavioral end point that specifically
mimics large vessel cardioembolic stroke in animals.
However, since tPA improves outcome of all three of these
stroke types in humans, an embolic animal model that
represents any of the subtypes might be considered as a
potential model to develop new treatments.
Evaluation of Neuroprotective Agents
Since only tPA has been approved by the FDA, the
translational power of the RSCEM is relatively unknown,
but there are numerous new data to support our contention
that the RSCEM should be used for translational research.
Recently, the free radical scavenger NXY-059 was tested in
multiple clinical trials based upon significant efficacy in
rodent and marmoset models of stroke [66–71]. The
following section will evaluate the preclinical and clinical
Table 1 Correlative analysis of tPA effects in rodent embolic stroke models
Research group Treatment time and pharmacological result
Chopp [48, 100] 1 h: decreased infarct volume
2 h: decreased infarct volume
4 h: increased BBB leakage, no behavioral improvement and no change in infarct volume
Lo [49, 51] 2 h: decreased infarct volume
6 h: confluent hemorrhagic infarction and both infarction and neurological deficits were worsened by tPA
Fisher [101] 3 h: hemorrhagic infarction type 2 hemorrhages
Overgaard [52, 53]1 5 m –2 h: reduced the infarct volume and improved the clinical score when administered up to 2 h following stroke
4 h: prolonging the delay of treatment increased the infarct volume
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scavenger NXY-059 and compare them to hydrophobic free
radical scavenger edaravone, a compound that is used in
Japan to treat AIS.
NXY-059
Centaur Pharmaceuticals, Renovis Inc., and Astra-Zeneca
Inc. attempted to develop disodium-[(tert-butylimino)meth-
yl]benzene-1,3-disulfonate-N-oxide (NXY-059), a water-
soluble lead nitrone [72]. The rationale for choosing this
compound is not clear since the addition of two sulfonyl
groups significantly reduced the ability of the drug to
effectively cross the BBB [73, 74], thus limiting its activity
outside of the vascular compartment [73].
The impetus for rapid development of NXY-059 was
based upon Astra-Zeneca-supported preclinical evidence
from rodent studies and a marmoset permanent MCAO
stroke model (reviewed in [6, 75]). In rats with transient
focal ischemia produced by occlusion of the MCA, neuro-
protection measured by improved behavioral scores could
be observed if NXY-059 was administered up to 6 h
following occlusion [70, 73]. In the primate permanent
MCA occlusion model, NXY-059 reduced spatial percep-
tion neglect and decreased gray and white matter damage
[67], with a therapeutic window of 4 h when the drug was
infused for 24-48 h. However, ischemia produced by
invasive permanent occlusion of the MCA (i.e., method
from Marshall et al. [66–68]: “After turning a large cranial
flap and opening the dura over the right lateral frontal
cortex, the right M1 segment of the MCA, 2 mm medial to
the olfactory tract, was permanently occluded. The vessel
was both occluded and bisected by electrocoagulation at
this site”) does not mimic the clinical presentation of
embolic stroke.
To generate a better understanding of the potential of
NXY-059 as a treatment, we used a more representative
animal model of human embolic stroke. Using the RSCEM,
generic NXY-059 (synthesized and validated at the
VASDHS by Dr. Robert Purdy and identified as NXY-
059 g) was shown to reduce embolism-induced behavioral
dysfunction when the drug was administered up to 1 h after
the insult, but not thereafter [44, 76]. Thus, there was a
clear difference between the therapeutic window derived
from the rodent/marmoset model (i.e., 4–6 h) vs. the
embolic stroke model (i.e., 1 h). Nevertheless, even though
these data were presented in the peer-reviewed literature
during the early development of NXY-059, Astra-Zeneca
Inc. and Renovis Inc. continued with the development of
NXY-059 as described below. It is interesting to note that
Bath et al. [75] recently stated that NXY-059 was neuro-
protective in experimental stroke based upon 15 Astra-
Zeneca-supported studies involving rats (544), mice [9],
and marmosets [32], although “bias” may have resulted in
efficacy being overestimated.
Phase III clinical trials, designated as the Stroke Acute
Ischemic NXY-059 Treatment (SAINT I and II) conducted
by Astra-Zeneca assessed the efficacy profiles of the
investigational drug NXY-059 in stroke patients. In the
first trial, 2,270 mg of NXY-059 was infused per hour,
reduced after the first hour to 480–960 mg/h for 71 h [77].
The claim was made that a target concentration of
260 umol/l was to be achieved. In the trial, 1,722 AIS
patients received a 72-h infusion of placebo or NXY-059
within6ho fstroke onset [77]. The primary outcome,
defined as disability at 90 days and assessed according to
the mRS (p=0.038) for disability, was only slightly
improved, but other outcome measures like neurological
functioning measured by the NIHSS were not [77]. In the
follow-up SAINT II trial, 1,588 patients were treated the
same dosing regimen of NXY-059 that was used in SAINT
1[ 19], and the inclusion criteria as far as time to treatment
were the same. The mean time to treatment with NXY-059
was 3 h and 46 min, similar to that of SAINT I [19, 77].
SAINT II showed that NXY-059 did not meet its primary
outcome of a statistically significant reduction in stroke-
related disability, as assessed by the mRS (p=0.33, odds ratio
of 0.94). Subgroup analyses, including time to treatment, did
not demonstrate a treatment benefit. In addition, NXY-059
did not statistically significantly improve neurological status
vs. placebo on the NIHSS (p=0.70). The results of the
SAINT II trial were disappointing, but not unexpected in
light of the modest positive effect of NXY-059 in the SAINT
It r i a l .
In both SAINT trials, time to treatment (approximately
4 h) was well within the therapeutic window predicted by
the stringent preclinical permanent occlusion rodent and
marmoset model studies (approximately 4–6 h), but not that
predicted by the RSCEM (1 h, see Table 1). Thus, it is
likely that a combination of an inferior chemical compound,
poor CNS distribution, and a short therapeutic window
resulted in the lack of efficacy in over 3,400 AIS patients.
To summarize, NXY-059 g had a therapeutic window of
1 h in the RSCEM and no effective therapeutic window in
AIS patients when tested with a time to treatment of 3.76 h.
Thus, for this hydrophilic agent, the therapeutic window
ARR is 0.
Edaravone
Unlike the hydrophilic molecule NXY-059 described
above, Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one,
Radicut, MCI-186) is a low-molecular-weight free radical
scavenger that readily crosses the BBB [78, 79]. The
preclinical experience with edaravone is quite extensive
since it has been under development by Mitsubishi-Tokyo
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79]. Like NXY-059, edaravone has the potential to scavenge
free radicals, but its activity is not limited to the vascular
compartment because of its hydrophobic properties.
In the RSCEM, edaravone administered subcutaneously
decreased behavioral deficits for the treated population
when administered 5 and 60 min post-embolization [47].
For the early post-embolization time to treatment, the
behavioral increases were in the range of 94–195% over a
standard vehicle control, in this case dimethylsolfoxide.
More importantly, when edaravone was administered 3 h
following embolization, there was still a significant increase
in behavior, but edaravone was inactive when applied 6 h
following embolization. The study using the RSCEM
indicates that edaravone may have substantial therapeutic
benefit for the treatment of AIS, and the drug had a
therapeutic widow of at least 3 h in rabbits.
The use of edaravone to treat stroke remains controver-
sial, mainly because there have not been randomized
double blind international trials to support the use of the
drug. That point is duly acknowledged, however, based
upon Japanese clinical trials in stroke patients. Mitsubishi-
Tokyo Pharmaceutical Inc. (Tokyo, Japan) has obtained
approval from the regulatory agency in Japan for the
treatment of AIS patients with edaravone if the drug was
administered within 72 h of the ischemic event [78–83].
Suda et al. [84] have proposed that edaravone, when given
within 3–6 h of a cardioembolic stroke, can salvage the
boundary zone of the infarct in patients (i.e., ischemic
penumbra) and reduce the extent of edema, presumably
resulting in clinical improvement. Yoshifumi [85] reported
preliminary findings of a clinical trial showing that patients
treated with edaravone prior to administration of intrave-
nous tPA had a reduced incidence of hemorrhage compared
to tPA-treated patients [85]. Thus, the Japanese experience
with edaravone suggests that the drug is superior, in many
ways, to the failed Astra-Zeneca spin trap agent NXY-059
[19, 86]. Nevertheless, outside of Japan, there has been
little interest in the clinical development of edaravone for
the treatment of AIS.
In a 2009 study by Sinha et al. [87], the first Indian
experience with edaravone was published. Twenty-two AIS
patients were given 30 mg of edaravone twice daily for
14 days by infusion. The mean time to treatment following
onset was 26.5±21.27 h. The study used mRS and Barthel
index (BI) measured up to 90 days following treatment. In
the study, 68% of patients had a favorable outcome where
the mean mRS score decreased from 4.01±0.92 at baseline
to 1.86±1.07 at day 90 (p<0.005), and the mean BI
increased from 40.00±30.11 at baseline to 75.62±22.86 at
day 90 (p<0.005). This was the first confirmation that
edaravone had efficacy in patients and that the effect could
be observed with a long therapy.
Although edaravone is purported to have significant
benefit in stroke patients, there may be an increased risk of
renal toxicity associated with its administration [88]. It has
been reported that approximately 45% of patients with
edaravone-induced renal toxicity recover renal function
after edaravone treatment is stopped [88]. This toxicity was
not observed by Sinha et al. [87].
The current therapeutic window information for edar-
avone from the RSCEM [47] appears to be at odds with the
current clinical trial information which suggests that edar-
avone may be used 24–72 h following a stroke [78–83]. In
contrast to the original trial report where a significant
difference between edaravone-treated and placebo-treated
groups measured using the mRS (p=0.0382) was reported,
Inatomi et al. [82] showed that edaravone could only
produce a modest clinical improvement in AIS patients,
with NIHSS≤7, efficacy that was not seen in the moderate to
severe AIS patients (NIHSS > 7). Moreover, the authors
report that 6 months after AIS onset, patients who became
independent (mRS<2) were more likely to have received
edaravone than placebo (41% vs. 28%, p=0.066). Since the
results from Sinha et al. [87] are positive and promising, it
appears that edaravone may have some utility in the
treatment of AIS, but additional fully randomized clinical
trials are essential for FDA approval of this free radical
scavenger.
To summarize, edaravone has a therapeutic window of
3 h in the RSCEM and an effective therapeutic window of
24–72 h in AIS patients. Thus, for this hydrophobic agent,
the therapeutic window ARR is 8–24.
Transcranial Near-Infrared Laser Therapy
A growing body of scientific literature exists documenting
the photo-biostimulation effects of infrared laser therapy
both in vitro and in vivo [89–91]. Recently, irradiation with
specific infrared wavelengths that penetrate deep into the
brain [90] was shown to stimulate adenosine triphosphate
(ATP) formation by mitochondria, an effect thought to be
mediated by the mitochondrial chromophore cytochrome c
oxidase [39]. The overall result of laser treatment is
postulated to induce improved energy metabolism and,
potentially, enhanced cell viability. See the review by
Lapchak et al. [40] for a detailed discussion of near-
infrared laser irradiation therapy (NILT) safety, efficacy,
and mechanism of action.
In the RSCEM, transcranial NILT was shown to be safe
and promoted significant behavioral improvement if treat-
ment was initiated up to 6 h following embolization [46].
Moreover, the effect of NILT was durable and improve-
ments in behavior could be still measured 21 days after
embolization and a single treatment. Therefore, on the basis
of the results with the RSCEM, we concluded that NILT
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AIS. The main advantage to develop NILT is the long
therapeutic window in the RSCEM. We have recently
shown that NILT treatment can significantly increase
cortical ATP content in embolized rabbits [39, 40],
suggesting that NILT-induced behavioral improvement
may be related to improved mitochondrial function.
Subsequently, a number of studies using the rat MCA
occlusion model sponsored by PhotoThera Inc. (Carlsbad,
CA, USA) have been published [89, 91]. In contrast to the
results in the RSCEM in which laser irradiation promoted
significant neuroprotection when applied up to 6 h post-
embolization [46, 92] and a non-significant improvement
when applied 12 h following embolization [46], in the rat
MCAO model, laser treatment was only effective when
applied 24 h, but not 4 h or less, after stroke onset [89, 91].
The positive results documented for NILT in animal models
of stroke, especially the long therapeutic window in the
RSCEM (Table 2), prompted the rapid initiation of the
Neurothera Effectiveness and Safety trial (NEST-I), a
prospective, intent-to-treat, multicenter, international,
double-blinded trial sponsored by PhotoThera Inc. [93].
The preliminary results from 120 AIS patients with a
treatment time of 2–24 h (median time 18 h) showed that
more patients in the laser-treated group had successful
outcomes from baseline to 90 days, measured by a mean
change in the NIHSS and mRS, than did controls (p=0.035,
stratified by severity and time to treatment; p=0.048,
stratified by severity alone). Based upon the promising
results of the NEST-I trial, the NEST-2 trial, a double-blind,
placebo (sham) controlled trial was initiated in 57 centers in
four countries [94]. In the trial, 337 patients were
randomized to the NILT group and 327 to the sham group.
For NEST-2, the time to treatment was 14.6±5.9 and 14.7±
6.1 h for the NILT and sham groups, respectively, with a
maximum time to treatment of 23.9 h in each group. Unlike
NEST-1 where the NIHSS and mRS scales were used for
efficacy assessment, NEST-2 used mRS as the primary end
point and subsequently NIHSS was used for post hoc
analysis. Using mRS, the primary efficacy end point was a
favorable 90-day score of 0 to 2 assessed by the modified
Rankin Scale. One hundred and twenty patients (36.3%) in
the NILT group achieved favorable outcome vs. 101
(30.9%) in the sham-treated group (p=0.094, odds ratio
1.38, 95% CI 0.95–2.00). When viewed to include all
patients enrolled in each treatment group, there was no
overall significant effect of NILT; however, with the
numbers enrolled in each group, the study may have been
underpowered. However, a post hoc analysis of patients
with a baseline NIHSS of <16 showed a favorable outcome
at 90 days on the primary end point (p<0.044). It is
interesting to note that the authors documented a mean
NIHSS score of 13.1±4.7 and 13.2±4.6, respectively, for
the NILT and sham-treated groups, which is well within the
range of the specific group (i.e., NIHSS<16) shown to have
significant behavioral improvement when the post hoc test
was done. Clearly, NILT does have a physiological effect in
AIS patients, and there is a long therapeutic window of
opportunity for treatment (approx. 14–24 h). However, it is
possible that not all patients will respond to this novel form
of treatment when applied as a monotherapy.
To summarize, NILT has a therapeutic window of 6 h in
the RSCEM and an effective therapeutic window of (mean
time to treatment from NEST-2) of 14.6 h in AIS patients.
Thus, for this novel method of neuroprotection, the
therapeutic window ARR is 2.43.
Model Hypothesis Testing
Based upon the above preclinical and clinical studies with
different classes of treatments including an FDA-approved
thrombolytic, free radical scavengers and a laser device, we
hypothesize that the RSCEM can be used as an effective
translational tool to develop new stroke treatment. It is
Table 2 Correlative analysis: RSCEM vs. AIS patients
Therapy Effect in RSCEM
a Effect in AIS patients
b TW (AIS/rabbit) ARR
tPA Improved behavior [33, 45] Improved clinical scores 3–4.5/1–1.5 ARR 3
Therapeutic window 1–1.5 h Therapeutic window 3–4.5 h, [14, 16, 95]
NXY-059 Improved behavior [44, 76] No effect when administered within a TT of 3.76 h of a stroke [19, 77] No efficacy/1 ARR 0
Therapeutic window 1 h
Edaravone Improved behavior [47] Improved clinical scores 24–72/3 ARR 8–24
Therapeutic window 3 h Therapeutic window 24–72 hours [78–83, 87]
NILT Improved behavior [46] Improved clinical scores with caveat of patients having an NIHSS<16 14.6/6 ARR 2.43
Therapeutic window 6 h Therapeutic window TT 14.6 h [94]
TT time to treatment, TW therapeutic window, ARR AIS/RSCEM ratio
aRSCEM end point—behavior using the analysis using quantal analysis
bAIS patient endpoint—clinical rating scores using NIHSS and/or mRS
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development of stroke treatments, we are hypothesizing
that the RSCEM is useful for incrementally advancing the
translational development of treatments. However, it is
essential that the more common rodent models widely used
by the majority of stroke researchers should continue to be
used for initial drug screening and for the study of
mechanisms following stroke insults.
For translational drug development purposes, the FDA-
approved drug tPA is the current standard to which all other
treatments must be compared. If one were comparing two
thrombolytics, one would require that the test thrombolytic
be equally efficacious or more so than tPA in the RSCEM.
Not only should the new thrombolytic be efficacious, it
should also have a therapeutic window equivalent to or
longer than the original compound. This same logic should
also apply to non-thrombolytic “neuroprotectants” and
other novel forms of AIS therapy. That is, the behavioral
improvement observed with tPA in the RSCEM must be
matched by any proposed “therapy” in order for one to
predict that the drug will be useful in human stroke. The
logic is the following: the thrombolytic protects tissue by
opening up closed vessels, and this appears to be
independent of clot source based upon the NINDS tPA
trial [16]. The “therapy” supports cell survival in the
presence or absence of thrombolysis, and the degree of
behavioral improvement must be equivalent to or better
than that observed with tPA in order for an effect on
behavior to be observed in humans with stroke. If the
behavioral outcome of a new “therapy” is inferior to the
behavioral outcome of tPA in the RSCEM, it probably will
not be a successful treatment in human stroke. Stated
another way, if the behavioral improvement (i.e., neuro-
protection obtained without reperfusion) is similar to or
better than the improved behavioral outcome obtained
with thrombolysis with tPA, then this new “therapy”
likely could show significant clinical benefit in human
stroke.
The approach just mentioned stands in marked contrast
to the majority of stroke studies performed in animals. In
most animal studies, a “therapy” is compared to a “saline or
vehicle control,” and almost every animal study reports a
statistically significant positive result based upon decreased
infarct volume and/or behavioral improvement on an
arbitrary behavioral scale. However, there is no way to
know how these results translate to improving behavioral
outcomes in human stroke victims. Indeed, the only known
paradigm is tPA treatment in the RSCEM because the
model was used to develop tPA. A rational strategy for
assessing new therapies in the future should include a
comparison of therapy and vehicle in the RSCEM that also
includes tPA treatment in both groups. If it can be
demonstrated that the new therapy has a longer therapeutic
window than tPA and if the therapy improved behavior,
then the clinical design may include combination therapy
and additional groups of patients with therapy alone as long
as the combination would not be contraindicated (i.e., the
new therapy would have detrimental effects in combination
with tPA or in some way inhibit the activity of tPA).
A Model Basis for Effective Translation
Translating results of experimental stroke treatments from the
laboratory bench to the patient’s bedside has proven difficult.
In the RSCEM, tPA effectively improved scores when given
1–1.5 h following embolization, and in patients, the therapeu-
ticwindowisalongtheorderof3–4.5hafterstrokeonsetfora
thrombolyticthatincreasescerebralperfusion[14, 16, 95]. By
inference, it was judged that the differential between the
observed time of effectiveness in the model and in patients
would be two to threefold [95]. That is, when drugs have a
therapeutic window of 1 h in embolized rabbits, a window of
2–3 h would be expected in stroke patients. Consistent with
this, in the RSCEM, edaravone is effective up to 3 h
following embolization [47] and has now been shown at
multiple clinical sites to be effective when given 24–72 h
after a stroke [82, 83, 87, 96]. Moreover, in the RSCEM,
laser irradiation was effective up to 6 h following a stroke
[46], and as predicted by the model, the NEST-I trial [93]
found that laser therapy improved clinical rating scores if
patients were treated within 24 h following a stroke. In
addition, the NEST-2 trial provided additional evidence that
laser therapy could be used effectively with a mean time to
treatment of 14 h [94] if the correct population of patients is
studied.
The results from the preclinical and clinical development
of the different types of stroke treatment described above
suggest that success can be achieved if an optimal
preclinical model is used to develop the new treatment
and if the treatment is compared to an FDA-approved
standard of care. The correlative data presented suggest that
there is a distinct relationship between the therapeutic
window that can be achieved in the RSCEM and a window
of opportunity to treat in AIS patients. The correlation may
depend somewhat upon the type of treatment being
translated from animal to human whether it be pharmaceu-
tical or device-derived. The data have been consolidated in
Table 2 and presented in two columns for direct compar-
ison. Based upon 2 of the comparisons, the ARR is 2.43–3.
This indicates that a treatment that is effective at 1 h in the
RSCEM would be effective up to 3 h in AIS patients. Of
course, the data for edaravone are outliers to this hypothesis
that cannot be easily explained. For edaravone, the current
ARR is 8–24, which appears anomalous for the following
reason. If we use the minimum ratio of 8 and take into
consideration that NXY-059 was effective for 1 h following
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have been predicted to be effective with a time to treatment
of 8 h in the SAINT II trial [19]. If we consider the ARR
correlation of 2.43–3 resulting from the NINDS tPA and
NEST trial, then the maximum efficacy window for NXY-
059 predicted by the RSCEM would be in the range of
2.43–3[ 44, 76]. The fact that mean time to treatment for
NXY-059 used in the SAINT trial was 3.6 h would suggest
that NXY-059 would have been ineffective in AIS patients
based upon the RSCEM ratio. Indeed, NXY-059 failed in
the SAINT-2 trial [19].
The RSCEM has typically used 2- to 3-month-old male
rabbits as a screen for therapeutic efficacy measuring
behavior (primarily motor function) 1 or 2 days post-
embolization [44, 45, 76] and in the one study up to
21 days post-embolization [40, 46]. Even though there is
strong correlative data between the behavioral outcome
measured in rabbits (2–21 days post-stroke) and humans
(90 days) post stroke, there is a need to address long-term
outcomes in all preclinical models if they are to be used as
effective translational tools. The RSCEM has been useful to
predict “neuroprotective” treatment strategies administered
within 1-6 h of embolization. However, if a drug or novel
therapy targeting recovery of function is to be developed,
then behavioral monitoring times should be extended past
21 days to ascertain the effects of the treatments on
functional recovery.
Rabbit and Human Brain Differences
Besides the obvious anatomical feature differences between
the brain of the two species, which include differences in
size, shape, cortical folding, and gray/white matter ratios,
the exact reasons for the different therapeutic windows
between rabbit and man are not clearly understood.
However, the recent article by Karbowski [97]s h e d s
significant light on metabolic differences between the two
species when measured under normal conditions. In New
Zealand white rabbits, the basal metabolic rate (BMR) is
approximately 750 kcal m
−2 day
–1 [98], whereas the basal
rate in human is 720 kcal m
−2 day
–1 [99], a human/rabbit
ratio of 0.96. The BMR data for both species take into
consideration the “surface area law” about the “constant”
relationship between basal metabolic rate and surface area
[99]. It has been reported that total basal cerebral
metabolism rate (BCM) in human brain (average brain
weight 1,300 g) [97] is approximately 2.5-fold that of rabbit
brain (average brain weight 12 g) [97] and that there is
higher metabolism in gray matter compared to white matter
[97]. Karbowski [97] also states that “cerebral energy use
increases more steeply with brain size” than does BMR,
and this is evident with a BMR of 0.96 compared to a BCM
of 2.5. Thus, even though the BMR is similar between
rabbits and humans, there is a large difference in BCM
between the two species. The observation and/or correlation
that the ARR provided above is 2.43–3 and that the BCM is
approximately 2.5 suggests that the differential therapeutic
windows in the two species is in some way related to
cerebral energy metabolism. When BCM is taken into
consideration and ARR is expressed as ARR/BCM, the
correlation is 0.97–1.2. Thus, the correlative data suggest
that the ARR may in some way be related to cerebral
metabolism or energy utilization in the two species. Overall,
this review establishes a basis in order to move a drug
forward into a clinical trial, with the hopes of achieving a
statistically significant improvement in mRS or NIHSS.
Summary and Conclusions
It is clear from the last 30 years of stroke research that there
are no easy fixes for ischemic brain damage. At the present
time, the RSCEM appears to be a useful predictor of
positive outcome in stroke clinical trials when using NIHSS
or mRS as the main clinical end point. Needless to say, the
correlations hypothesized in this review of the RSCEM are
based upon three positive treatments, one of which is FDA-
approved, one of which is approved by the Japanese
government, and one novel treatment which will continue
to be scrutinized in the NEST-3 phase III clinical trial to be
initiated later in 2010. The short 1 h therapeutic window for
the failed spin trap agent treatment NXY-059 also lends
credence to the proposed hypothesis that the RSCEM could
be used as an effective screen during the translational
research process to determine if compounds should be
further developed or whether they should be abandoned.
Based upon the scientific justification presented in this
review, we hypothesize that the RSCEM should be used as a
potential “gold standard” model and translational tool in
order to gauge the clinical potential of new treatments so that
effective clinical trials can be developed to promote recovery
of function and improve the well-being of AIS patients.
If time is brain, then the therapeutic window derived
from saving rabbit brain following embolic strokes could
assist with preventing human brain death.
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